English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/99915
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorLodeiro, María-
dc.contributor.authorIbáñez, Clara-
dc.contributor.authorCifuentes, Alejandro-
dc.contributor.authorSimó, Carolina-
dc.contributor.authorCedazo-Mínguez, Ángel-
dc.date.accessioned2014-07-15T11:09:40Z-
dc.date.available2014-07-15T11:09:40Z-
dc.date.issued2014-
dc.identifierdoi: 10.3233/JAD-132063-
dc.identifiere-issn: 1875-8908-
dc.identifierissn: 1387-2877-
dc.identifier.citationJournal of Alzheimer's Disease 41(1): 223-232 (2014)-
dc.identifier.urihttp://hdl.handle.net/10261/99915-
dc.description.abstractIncreasing evidence suggest that Alzheimer's disease (AD) is a heterogeneous disorder that includes several subtypes with different etiology and progression. Cerebrospinal fluid (CSF) is being used to find new biomarkers reflecting the complexity of the pathological pathways within this disease. We used CSF and clinical data from patients to investigate the status of asymmetric dimethyl-L-arginine, creatine, suberylglycine, and L-carnitine along AD progression. These molecules play important roles in mitochondrial function and dysfunction in mitochondrial metabolism are involved in AD pathology. We found that non-APOE4 carriers show lower levels of L-carnitine in CSF early in AD. L-carnitine levels correlate with amyloid-β (Aβ) levels and Mini-Mental State Examination score, but do not add to the specificity or sensitivity of the classical AD CSF biomarkers, Aβ42, phospho-tau, and total-tau. Our results suggest APOE genotype-dependent differences in L-carnitine synthesis or metabolism along AD, and insinuate that L-carnitine treatments would be more beneficial for AD patients not carrying the APOE4 isoform. © 2014 - IOS Press and the authors. All rights reserved.-
dc.description.sponsorshipThis research was supported by grants from Sweden: Swedish Brain Power, Alzheimerfonden, Gun och Bertil Stohnes Stiftelse, Karolinska Institutet fund for geriatric research, Stiftelsen Gamla Tjänarinnor, Stiftelsen Lars Hiertas Minne, Stiftelsen Dementia, Demensförbundet and the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and the Karolinska Institute.-
dc.publisherIOS Press-
dc.relation.isversionofPostprint-
dc.rightsopenAccess-
dc.subjectAPOE4-
dc.subjectCerebrospinal fluid-
dc.subjectAlzheimer's disease-
dc.subjectBiomarkers-
dc.subjectL-carnitine-
dc.titleDecreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease-
dc.typeartículo-
dc.identifier.doi10.3233/JAD-132063-
dc.relation.publisherversionhttp://dx.doi.org/10.3233/JAD-132063-
dc.date.updated2014-07-15T11:09:40Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.contributor.funderSwedish Brain Foundation-
dc.contributor.funderSwedish Alzheimer Foundation-
dc.contributor.funderKarolinska Institute-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004047es_ES
Appears in Collections:(CIAL) Artículos
Files in This Item:
File Description SizeFormat 
Decreased CSF levelsE4.pdf1,28 MBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.